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Abstract
Single nucleotide polymorphisms (SNPs) in the genes encoding the fatty acid desaturase
(FADS) and elongase (ELOVL) enzymes affect long-chain polyunsaturated fatty acid (LC-
PUFA) production. We aimed to determine if these SNPs are associated with body mass
index (BMI) or affect fatty acids (FAs) in pregnant women. Participants (n = 180) from the
PREOBE cohort were grouped according to pre-pregnancy BMI: normal-weight (BMI =
18.5–24.9, n = 88) and overweight/obese (BMI25, n = 92). Plasma samples were analyzed
at 24 weeks of gestation to measure FA levels in the phospholipid fraction. Selected SNPs
were genotyped (7 in FADS1, 5 in FADS2, 3 in ELOVL2 and 2 in ELOVL5). Minor allele car-
riers of rs174545, rs174546, rs174548 and rs174553 (FADS1), and rs1535 and rs174583
(FADS2) were nominally associated with an increased risk of having a BMI25. Only for the
normal-weight group, minor allele carriers of rs174537, rs174545, rs174546, and rs174553
(FADS1) were negatively associated with AA:DGLA index. Normal-weight women who
were minor allele carriers of FADS SNPs had lower levels of AA, AA:DGLA and AA:LA
indexes, and higher levels of DGLA, compared to major homozygotes. Among minor allele
carriers of FADS2 and ELOVL2 SNPs, overweight/obese women showed higher DHA:EPA
index than the normal-weight group; however, they did not present higher DHA concentra-
tions than the normal-weight women. In conclusion, minor allele carriers of FADS SNPs
have an increased risk of obesity. Maternal weight changes the effect of genotype on FA lev-
els. Only in the normal-weight group, minor allele carriers of FADS SNPs displayed reduced
enzymatic activity and FA levels. This suggests that women with a BMI25 are less affected
by FADS genetic variants in this regard. In the presence of FADS2 and ELOVL2 SNPs,
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overweight/obese women showed higher n-3 LC-PUFA production indexes than women
with normal weight, but this was not enough to obtain a higher n-3 LC-PUFA concentration.
Introduction
During pregnancy, the mother is the sole source of key nutrients for the fetus, such as n-6 and
n-3 long-chain (LC) polyunsaturated fatty acids (PUFAs) [1–3]. Studies have shown that ara-
chidonic acid (AA; C20:4n−6) and particularly docosahexaenoic acid (DHA; C22:6n−3), play
an important role in many physiological conditions [4], such as neural and visual development
[1, 3, 5]. Hyperlipidemia develops in normal pregnancy; accordingly, it has been observed that
levels of fatty acid (FA), such as DHA, increase in maternal plasma during pregnancy. Never-
theless, a higher activity of the enzymes encoded by the FADS and ELOVL genes could also be
related to this hyperlipidemia [6]. Due to the beneficial effects of n-3 LC-PUFAs, it is recom-
mended to increase their intake during pregnancy [4]. This is in contrast with the effect of
excessive n-6 FA intake, which may lead to maternal obesity and obesity-related complications
such as an increased risk of cardiovascular disease [7, 8]. Moreover, obese pregnancies lead to
a higher risk of obesity in newborn babies, thereby increasing the likelihood of lifelong obesity
and obesity-related complications [9, 10].
Apart from diet, LC-PUFAs can be obtained via endogenous synthesis from their essential
n-6 and n-3 PUFA precursors: linoleic acid (LA) and α-linolenic acid (ALA), respectively [1]
(S1 Fig). This process requires desaturation and elongation reactions, which are catalyzed by
delta-5 and delta-6 fatty acid desaturases (encoded by FADS1 and FADS2 genes, respectively)
and elongases (encoded by ELOVL gene (elongation of very long chain fatty acids)) [1, 11, 12].
The n-3 and n-6 series compete for these enzymes since they participate in both pathways. Sin-
gle nucleotide polymorphisms (SNPs) in these genes may affect LC-PUFA production, and
consequently alter FA levels [12]. For instance, minor allele carriers of the FADS1, FADS2 and
ELOVL2 genes, have been linked to lower LC-PUFA production, and consequently they show
increased concentrations of substrates and decreased levels of products in the LC-PUFA meta-
bolic pathway [1, 12–15].
Certain SNPs in the FADS gene have been linked to diseases such as coronary artery disease
[16] and type 2 diabetes [17]. Obesity is related to these conditions and is already known to
affect lipid metabolism during pregnancy [18]; however, to the best of our knowledge, mater-
nal obesity has not yet been directly linked to SNPs in the FADS and ELOVL genes.
Current studies analyzing the impact of FADS and ELOVL polymorphisms on FA levels are
not properly comparable because their analyses include different tissue samples, FAs and SNPs.
Given the impact of both obesity and SNPs on LC-PUFA production, the association between
obesity and SNPs in FADS and ELOVL genes is of interest. These nutritional studies involving
pregnant women are of great importance since the synthesis of LC-PUFA is induced in preg-
nancy and therefore the SNPs might have a different effect on pregnant women than on the
general population. Thus, the aim of this study was to determine if FADS and ELOVL genetic
variants are associated with body mass index (BMI) or affect PUFA levels in pregnant women.
Materials and methods
Study design and participants
The study complies with the Declaration of Helsinki. The protocol was approved by the medi-
cal ethics committees of the Clinical University Hospital San Cecilio and the Mother–Infant
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Hospital in the city of Granada, Spain. Written informed consent was obtained from all the
participants at the beginning of the study.
Pregnant women (n = 180) were selected from the 331 individuals participating in the
observational PREOBE cohort study (study of maternal nutrition and genetics on fetal adipos-
ity programming) [19]. Participants were recruited at the Clinical University Hospital San
Cecilio and the Mother–Infant Hospital in the city of Granada, Spain, where samples and
information were also collected. Study design and information on PREOBE participants are
exhibited in Fig 1.
The inclusion criteria were singleton pregnancy, gestation between 12 and 20 weeks at
enrollment, and intention to deliver at the centers involved. Women were excluded if they
were participating in other research studies, if they had been receiving drug treatment or sup-
plements of either DHA or folate for more than the first 3 months of pregnancy, if they were
suffering from disorders such as hypertension, pre-eclampsia, fetal intrauterine growth retar-
dation, infections, hypo- or hyperthyroidism or hepatic renal diseases, or if they were follow-
ing an extravagant or vegan diet. Using questionnaires and medical records, baseline and
background characteristics were recorded such as maternal age, pre-pregnancy BMI, parity,
smoking status, diet, alcohol drinking habits, socio-demographic information, educational
level, and weight gain during pregnancy.
For this study, 180 pregnant women were divided into two groups according to their pre-
pregnancy BMI, normal-weight (BMI = 18.5–24.9, n = 88) and overweight/obese (BMI25,
n = 92). Plasma samples were collected at 24 weeks of gestation for FA analysis. Seventeen
SNPs (7 in the FADS1 gene, 5 in FADS2, 3 in ELOVL2 and 2 in ELOVL5) out of the 32 initially
selected were successfully genotyped and included in the analysis (S2 Table).
DNA analysis
Maternal material for DNA analysis was collected by scraping the inside of the cheek of the
pregnant participants with a buccal swab. Thirty-two SNPs in genes involved in lipid metabo-
lism (FADS1, FADS2, FADS3, ELOVL2, ELOVL5, ELOVL6 and FASN) were initially genotyped
from 5 μl of maternal DNA mixed with 5 μl of 2X TaqMan1 OpenArray1 Genotyping Master
Fig 1. Participants in the PREOBE study and classification following BMI and gestational diabetes criteria.
https://doi.org/10.1371/journal.pone.0179135.g001
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Mix. The analysis was then performed with 3 μl of the mixture in a microplate using Taqman1
Open Array1 genotyping technology. The OpenArray1 instrument (which consists of a Dual
Flat Block GeneAmp1 PCR System 9700, Bio-Rad1 thermal cycler with a Slide Chambers
Dual-Block Alpha unit and Thermo Electron PX2 thermal cycler) and the corresponding
OpenArray1 SNP Genotyping Analysis software, located at the Autonomous University of Bar-
celona (UAB), were used for the analysis. The genotyping required two phases: a thermal cycle
(PCR amplification) and detection of the final fluorescence signal. The reagents used were sup-
plied by Applied Biosystem (Foster City, CA, USA).
Fatty acid analysis
At 24 weeks of gestation, blood was obtained by arm venipuncture. Plasma was separated by
centrifugation and immediately frozen and stored at -80˚C until analysis. FAs were deter-
mined in the phospholipid fraction using the method developed by Chisaguano et al. [20].
Plasma lipids were extracted using 2:1 dichloromethane:methanol and phospholipids were iso-
lated using solid-phase extraction (SPE). FA methyl esters from plasma phospholipids were
analyzed using fast gas chromatography with a flame ionization detector. The results were
expressed as percentages of the total FAs detected.
We analyzed the FAs involved in enzymatic reactions encoded by the FADS and ELOVL
genes (substrates, products or indexes (product/substrates)). Furthermore, we studied the n3:n6
ratios (eicosapentaenoic acid (EPA):AA and DHA:AA), associated with obesity risk [7, 21–23].
Statistical analysis
Statistical analysis was performed using the SPSS software (version 20.0; SPSS Inc., Chicago,
IL, USA). The Kolmogorov–Smirnov test was used to study the normal distribution of data;
non-normal data were natural-log transformed. The agreement of genotype frequencies with
Hardy-Weinberg equilibrium expectations was tested by the chi-square test. Due to the limited
sample size, heterozygotes and homozygous for minor alleles, were analyzed as one group.
SNPs were coded according to minor allele count (0 for major homozygotes and 1 for the car-
riers of at least one minor allele) and analyzed as a numerical variable. However, this codifica-
tion implies an additive and dominant model. The associations between SNPs and FAs were
analyzed using linear regression; while the associations between SNPs and obesity were ana-
lyzed by logistic regression. All associations were corrected for potential confounders such as
age, education, smoking status and energy intake. FA levels were compared using univariate
ANOVA. Since DHA supplementation was largely absent and it did not affect DHA levels in
plasma, supplementation data were omitted for parsimony. The Bonferroni correction was
applied to take multiple testing into account and p-value thresholds were set at 0.004, which
was applied within each trait.
Results
Population characteristics
The characteristics of the groups are shown in Table 1. Normal-weight women were more
likely to have a higher level of education and take DHA supplementation; while the over-
weight/obese group had a lower energy intake and weight gain during pregnancy. No differ-
ences were observed in dietary FA levels. S1 Table shows a comparison of plasma DHA
concentrations at 24 weeks of gestation between pregnant women who took DHA supplemen-
tation and those who did not. After finding that the participants who reported taking DHA
supplement (n = 17) did not have higher serum DHA concentrations (p = 0.636) than the
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PLOS ONE | https://doi.org/10.1371/journal.pone.0179135 June 9, 2017 4 / 16
participants who did not take supplements (n = 93), we decided to include all the subjects in
the analysis regardless of supplement use.
S2 Table presents the characteristics of the studied SNPs, including the distribution of par-
ticipants in each allele group (major homozygotes, heterozygotes and minor homozygotes).
Normal-weight women tended to be major homozygotes for all the FADS1 and FADS2 SNPs
studied, while women in the overweight/obese group were mostly heterozygotes. Regarding
ELOVL2 SNPs, both groups presented mostly heterozygous alleles, and no pattern was
observed for ELOVL5 SNPs.
Association between SNPs and fatty acids
Table 2 shows nominal and significant associations between PUFA levels and FADS and
ELOVL SNPs after adjusting for age, education, smoking status and energy intake (the com-
plete analysis can be found in S3 Table). The most significant associations (p0.004) were
only found in the normal-weight group, where minor allele carriers of rs174537, rs174545,
rs174546 and rs174553 (FADS1) were negatively associated with the AA:dihomo-gamma-lino-
lenic acid (DGLA) index.
Association of FADS SNPs with obesity risk
After adjusting for age, education, smoking status and energy intake, participants who were
minor allele carriers of rs174545, rs174546, rs174548 and rs174553 (FADS1), and rs1535 and
rs174583 (FADS2) were nominally associated (p<0.05) with an increased risk of having a
BMI25, compared with two major allele carriers (Table 3).
Fatty acid levels according to genotype and weight
Plasma LC-PUFA levels according to genotypes are presented in Tables 4 and 5 (the complete
analysis can be found in S4 Table). Significant differences were found for normal-weight
Table 1. Characteristics of the population.
NORMAL-WEIGHT (n = 88) OVERWEIGHT/OBESE (n = 92) P
Mean (SD) Mean (SD)
Age (years) 30.91 (4.09) 30.64 (4.20) 0.665
Pre-pregnancy BMI (kg/m2) 22.00 (1.64) 30.33 (4.20) <0.001*
Weight Gain (kg) 12.64 (5.47) 9.19 (6.29) 0.001*
Education (%)
<Highschool 10.23% 15.38% 0.401
Highschool 15.91% 19.78%
>Highschool 73.86% 64.84%
Smoking during pregnancy (%) 21.92% 27.27% 0.447
DHA supplementation during pregnancy (%) 25.00% 7.61% 0.002*
Dietary intakes
Energy intake (kcal/d) 2177.54 (335.41) 1938.07 (591.28) 0.017
EPA intake (g/d) 0.13 (0.13) 0.12 (0.10) 0.713
DHA intake (g/d) 0.25 (0.20) 0.27 (0.18) 0.646
AA intakes (g/d) 0.13 (0.07) 0.13 (0.06) 0.98
P-value derived from global ANOVA and significance level (p0.004) was adjusted for multiple testing by Bonferroni correction. P-values <0.05 are
highlighted in bold and significant associations that persisted after Bonferroni correction are additionally denoted by stars (*p< 0.004). BMI: body mass
index; AA: arachidonic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
https://doi.org/10.1371/journal.pone.0179135.t001
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Table 2. Associations between plasma proportions of PUFAs and FADS and ELOVL polymorphisms.
Fatty acid Gene SNP Major/minor
allele
NORMAL-WEIGHT OVERWEIGHT/OBESE
N β P N β P
FADS1 indexes
AA:DGLA
FADS1 rs174537 G/T 22 -0.81 0.004* 18 -0.48 0.155
FADS1 rs174545 C/G 28 -0.70 0.003* 17 -0.48 0.174
FADS1 rs174546 C/T 28 -0.70 0.003* 19 -0.49 0.139
FADS1 rs174553 A/G 28 -0.70 0.003* 19 -0.49 0.139
FADS1 rs174547 T/C 23 -0.67 0.013 18 -0.48 0.155
FADS2 indexes
DGLA:LA
FADS2 rs1535 A/G 26 0.56 0.029 18 0.42 0.226
FADS2 rs174583 C/T 27 0.53 0.040 19 0.41 0.226
FADS2 rs99780 C/T 25 0.54 0.042 18 0.42 0.226
ELOVL2 indexes
DHA:DPAn3
ELOVL2 rs2236212 G/C 25 -0.05 0.806 19 -0.58 0.016
ELOVL2 rs3798713 G/C 25 0.00 0.995 19 -0.58 0.016
Fatty acids involved in FADS1 indexes
C20:3n6 (DGLA)
FADS1 rs174537 G/T 22 0.75 0.012 18 0.53 0.119
FADS1 rs174545 C/G 28 0.57 0.028 17 0.52 0.137
FADS1 rs174546 C/T 28 0.57 0.028 19 0.52 0.118
FADS1 rs174553 A/G 28 0.57 0.028 19 0.52 0.118
FADS1 rs174547 T/C 23 0.60 0.034 18 0.53 0.119
C20:4n6 (AA)
FADS1 rs174545 C/G 28 -0.55 0.042 17 -0.01 0.977
FADS1 rs174546 C/T 28 -0.55 0.042 19 -0.01 0.971
FADS1 rs174553 A/G 28 -0.55 0.042 19 -0.01 0.971
C18:3n3 (ALA)
FADS1 rs174537 G/T 22 0.71 0.027 18 -0.09 0.790
FADS1 rs174547 T/C 23 0.66 0.026 18 -0.09 0.790
Fatty acids involved in FADS2 indexes
C18:3n6 (GLA)
FADS2 rs174575 C/G 22 0.12 0.672 19 0.64 0.031
C20:3n6 (DGLA)
FADS2 rs1535 A/G 26 0.65 0.010 18 0.53 0.119
FADS2 rs174583 C/G 27 0.62 0.015 19 0.52 0.118
C18:3n3 (ALA)
FADS2 rs174575 C/G 23 0.50 0.043 19 0.22 0.494
C20:5n3 (EPA)
FADS2 rs99780 C/T 25 0.52 0.035 17 0.11 0.749
C22:5n3 (DPAn3)
FADS2 rs99780 C/T 25 0.62 0.011 18 -0.41 0.173
Associations between SNPs and fatty acids were analyzed using linear regression. SNPs were coded
according to minor allele count and analyzed as a numeric variable. "β" = beta per minor allele standardized
per the major allele. All associations were adjusted for potential confounders such as age, education,
smoking and energy intake. P-values <0.05 are highlighted in bold and significant associations that persisted
after Bonferroni correction are additionally denoted by stars (*p0.004). LA: Linoleic Acid; GLA: γ-Linolenic
Acid; DGLA: Dihomo-γ-Linolenic Acid; AA: Arachidonic Acid; ALA: α-linolenic Acid; EPA: Eicosapentaenoic
acid; DPAn3: Docosapentaenoic acid n3; DHA: Docosahexaenoic acid.
https://doi.org/10.1371/journal.pone.0179135.t002
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women: minor allele carriers of FADS1 SNPs showed lower AA level and both AA:DGLA and
AA:LA indexes than major homozygotes; while minor allele carriers of FADS2 SNPs showed
lower AA and higher DGLA levels (p0.004). Overweight/obese women presented the same
tendencies, but without the results reaching statistical significance. No differences were found
between genotypes of ELOVL SNPs.
Significant differences were also shown when comparing groups of weight (p0.004).
Among the minor allele carriers of rs1535, rs174583 and rs99780 (FADS2), and rs2236212,
rs3798713 and rs953413 (ELOVL2), overweight/obese women showed a higher DHA:EPA
index than those in the normal-weight group (Table 4). Meanwhile, among minor alleles carri-
ers of rs174537, rs174545, rs174546, rs174553 and rs174547 (FADS1), and rs1535, rs174575,
rs174583 and rs99780 (FADS2), normal-weight women had higher levels of the substrate ALA
than those in the overweight/obese group. In addition, among the major homozygotes of
rs2397142 (ELOVL5), normal-weight women presented higher levels of EPA than women who
were overweight/obese (Table 5).
Maternal plasma n3:n6 ratios, according to genotype, are presented in S5 Table. Among the
minor allele carriers of rs3798713 (ELOVL2), normal-weight women had significantly higher
EPA:AA ratio than those who were overweight/obese. This trend was also found in all gene
clusters studied, even when comparing major homozygotes.
Table 3. Associations between FADS and ELOVL genes and maternal obesity.
Gene SNP Major/Minor alleles N BMI25 BMI25c
OR P ORc Pc
FADS1
rs174537 G/T 66 2.12 0.147 2.89 0.069
rs174545 C/G 79 2.34 0.074 3.11 0.032
rs174546 C/T 81 2.55 0.047 3.28 0.025
rs174548 C/G 82 3.11 0.015 3.18 0.021
rs174553 A/G 82 2.64 0.039 3.44 0.019
rs174561 T/C 44 0.56 0.351 0.43 0.217
rs174547 T/C 66 1.96 0.191 2.75 0.082
FADS2
rs1535 A/G 77 2.58 0.048 3.42 0.025
rs174575 C/G 70 1.57 0.351 1.77 0.273
rs174583 C/T 79 2.62 0.046 3.38 0.024
rs99780 C/T 71 1.75 0.261 2.37 0.122
rs174602 T/C 46 1.55 0.475 1.18 0.812
ELOVL2
rs2236212 G/C 76 0.76 0.568 0.88 0.805
rs3798713 G/C 75 0.67 0.430 0.81 0.708
rs953413 A/G 58 1.00 1.000 0.58 0.425
ELOVL5
rs2397142 C/G 79 0.78 0.573 0.75 0.556
rs9395855 T/G 54 0.50 0.316 0.50 0.345
The association between SNPs and obesity risk was analyzed with logistic regression. SNPs were coded according to minor allele count and analyzed as
numeric variable. BMI = Body Mass Index. OR = odds ratio per minor allele with the major allele as reference. ORc and Pc = are corrected values after
adjustment for age, education, smoking and energy intake. Nominal associations are highlighted in bold (p<0.05).
https://doi.org/10.1371/journal.pone.0179135.t003
Maternal weight and FADS and ELOVL genetic variants on fatty acid levels
PLOS ONE | https://doi.org/10.1371/journal.pone.0179135 June 9, 2017 7 / 16
Table 4. FADS1, FADS2 and ELOVL2 enzymatic indexes according to maternal SNPs and LC-PUFA levels in plasma.
Gene SNP Major/minor
allele
NORMAL-WEIGHT OVERWEIGHT/OBESITY P (MM) P (Mm+mm)
MM Mm+mm P MM Mm+mm P
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
FADS1 indexes
AA:LA
FADS1 rs174537 G/T 15 0.45 (0.08) 23 0.39 (0.09) 0.038 12 0.46 (0.07) 21 0.43 (0.08) 0.390 0.811 0.085
FADS1 rs174545 C/G 22 0.46 (0.09) 27 0.38 (0.08) 0.003* 13 0.47 (0.07) 22 0.42 (0.08) 0.071 0.877 0.171
FADS1 rs174546 C/T 22 0.46 (0.09) 27 0.38 (0.08) 0.003* 13 0.47 (0.07) 25 0.42 (0.08) 0.098 0.877 0.109
FADS1 rs174548 C/G 24 0.45 (0.08) 25 0.39 (0.09) 0.031 13 0.45 (0.08) 25 0.43 (0.08) 0.553 0.969 0.115
FADS1 rs174553 A/G 22 0.46 (0.09) 27 0.38 (0.08) 0.003* 13 0.47 (0.07) 25 0.42 (0.08) 0.098 0.877 0.109
FADS1 rs174547 T/C 15 0.45 (0.08) 23 0.39 (0.09) 0.040 12 0.46 (0.07) 20 0.43 (0.08) 0.427 0.950 0.124
AA:DGLA
FADS1 rs174537 G/T 15 3.14 (0.70) 23 2.20 (0.60) <0.001* 12 3.57 (1.73) 21 2.55 (0.80) 0.032 0.414 0.107
FADS1 rs174545 C/G 22 3.12 (0.65) 27 2.25 (0.57) <0.001* 13 3.48 (1.67) 22 2.51 (0.78) 0.025 0.362 0.183
FADS1 rs174546 C/T 22 3.12 (0.65) 27 2.25 (0.57) <0.001* 13 3.48 (1.67) 25 2.54 (0.74) 0.021 0.362 0.120
FADS1 rs174548 C/G 24 2.97 (0.65) 25 2.33 (0.70) 0.002* 13 3.42 (1.69) 25 2.57 (0.75) 0.037 0.244 0.246
FADS1 rs174553 A/G 22 3.12 (0.65) 27 2.25 (0.57) <0.001* 13 3.48 (1.67) 25 2.54 (0.74) 0.021 0.362 0.120
FADS1 rs174547 T/C 15 3.20 (0.67) 23 2.27 (0.55) <0.001* 12 3.54 (1.73) 20 2.56 (0.82) 0.037 0.291 0.194
FADS2 indexes
DGLA:LA
FADS2 rs1535 A/G 20 0.15 (0.04) 25 0.18 (0.05) 0.011 13 0.15 (0.04) 23 0.18 (0.05) 0.115 0.877 0.798
FADS2 rs174575 C/G 24 0.15 (0.04) 16 0.19 (0.06) 0.017 21 0.17 (0.06) 14 0.17 (0.05) 0.943 0.276 0.315
FADS2 rs174583 C/T 19 0.15 (0.04) 27 0.18 (0.05) 0.036 13 0.15 (0.04) 25 0.18 (0.05) 0.130 0.967 0.907
FADS2 rs99780 C/T 15 0.15 (0.04) 26 0.18 (0.05) 0.037 12 0.15 (0.05) 22 0.18 (0.05) 0.076 0.953 0.961
AA:LA
FADS2 rs1535 A/G 20 0.45 (0.08) 25 0.39 (0.09) 0.025 13 0.47 (0.07) 23 0.42 (0.08) 0.128 0.504 0.170
FADS2 rs174583 C/T 19 0.44 (0.08) 27 0.38 (0.08) 0.019 13 0.47 (0.07) 25 0.42 (0.08) 0.098 0.447 0.109
DHA:EPA
FADS2 rs1535 A/G 20 15.02 (5.64) 25 14.66 (5.92) 0.840 13 19.69 (6.63) 23 20.89 (7.87) 0.655 0.045 0.004†
FADS2 rs174575 C/G 24 16.41 (5.99) 16 13.41 (5.21) 0.119 21 20.99 (6.36) 14 20.27 (8.32) 0.778 0.018 0.012
FADS2 rs174583 C/T 19 15.02 (5.64) 27 14.48 (5.71) 0.753 13 19.69 (6.63) 25 20.58 (7.89) 0.737 0.045 0.003†
FADS2 rs99780 C/T 15 16.22 (5.52) 26 13.71 (4.76) 0.138 12 20.50 (6.29) 22 20.19 (8.14) 0.911 0.078 0.002†
FADS2 rs174602 T/C 19 16.06 (5.17) 13 14.76 (6.12) 0.531 23 19.97 (6.82) 14 18.02 (6.37) 0.393 0.046 0.199
DHA:DPAn3
FADS2 rs1535 A/G 20 10.84 (1.96) 25 10.03 (2.40) 0.232 13 11.14 (2.26) 23 11.58 (2.26) 0.577 0.687 0.027
FADS2 rs174575 C/G 24 10.58 (2.21) 16 10.15 (2.39) 0.574 21 11.23 (2.29) 14 12.20 (2.28) 0.230 0.334 0.026
FADS2 rs174583 C/T 19 10.76 (1.98) 27 10.13 (2.33) 0.350 13 11.14 (2.26) 25 11.53 (2.50) 0.642 0.613 0.044
FADS2 rs99780 C/T 15 11.04 (2.07) 26 9.83 (2.17) 0.090 12 11.42 (2.11) 22 11.41 (2.45) 0.990 0.640 0.024
ELOVL2 indexes
DPAn3:EPA
ELOVL2 rs2236212 G/C 14 1.51 (0.51) 29 1.48 (0.67) 0.876 13 1.66 (0.71) 22 1.88 (0.71) 0.388 0.530 0.047
ELOVL2 rs3798713 G/C 11 1.48 (0.52) 31 1.44 (0.67) 0.863 12 1.67 (0.74) 25 1.88 (0.70) 0.410 0.476 0.021
DHA:EPA
ELOVL2 rs2236212 G/C 14 16.39 (6.29) 28 14.45 (5.43) 0.307 13 20.58 (8.33) 22 20.05 (7.02) 0.841 0.151 0.003†
ELOVL2 rs3798713 G/C 11 15.48 (5.10) 30 13.96 (5.33) 0.418 12 20.76 (8.67) 24 20.13 (7.07) 0.819 0.094 <0.001†
ELOVL2 rs953413 A/G 10 15.33 (5.93) 25 14.78 (5.23) 0.789 7 21.14 (7.60) 20 20.88 (7.57) 0.939 0.096 0.003†
DHA:DPAn3
ELOVL2 rs2236212 G/C 14 10.87 (2.20) 29 10.14 (2.32) 0.337 13 12.57 (1.53) 22 10.77 (2.67) 0.032 0.029 0.375
(Continued )
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Discussion
The present study analyzed the effect of FADS and ELOVL genetic variants on a broad FA pro-
file. To the best of our knowledge, this is the first study to explore associations between FADS
and ELOVL SNPs, FA levels and maternal pre-pregnancy weight. Despite a lack of studies ana-
lyzing the association between obesity risk and FADS or ELOVL polymorphisms, some authors
have observed that minor alleles of rs174547 (FADS1) confer a higher risk of obesity-related
conditions, such as increased triglyceride levels and decreased high-density lipoprotein choles-
terol concentrations [24–26], as well as an increased risk of coronary disease [26, 27]. In the
present study, we found that women who carried at least one minor allele of the FADS1 and
FADS2 SNPs, were associated with a higher risk of having a BMI25 than homozygotes for
the major allele. This association could explain why most of the overweight/obese women
carried one minor allele copy and normal-weight women were mostly homozygous for the
major alleles. Both weight groups showed very similar distributions within the allele groups of
ELOVL SNPs; thus, we did not expect to find any associations between ELOVL genotypes and
weight.
In line with other studies [5, 12], we found that the FADS1 and FADS2 SNPs were associ-
ated with FAs, mainly from the n-6 series, and less with those from the n-3 series. The only sig-
nificant association (p-value0.004) was found in the normal-weight group, where minor
alleles of FADS1 were associated with a lower AA:DGLA index. Several nominal associations
were also found; nevertheless, they were mainly in normal-weight women and the n-6 series.
Regarding the overweight/obese group, minor allele carriers of rs2236212 and rs3798713
(ELOVL2) were nominally associated with a lower DHA:n-3 docosapentaenoic acid (DPAn3)
index. Barman et al. observed results similar to this last association, but their significance did
not persist after correction either [12].
We also observed that FADS genetic variants affected FA concentrations. Normal-weight
women who were minor allele carriers of FADS1 SNPs had significantly lower levels of product
(AA) and indexes (AA:LA and AA:DGLA) than major homozygotes. Consistently with this,
nominal differences were also observed; minor allele carriers of FADS1 SNPs showed nomi-
nally lower substrates (DGLA and ALA). This was previously reported by other authors [1, 5,
12, 13, 28, 29], who observed that minor allele carriers in FADS displayed lower FA indexes
and products, and increased amounts of substrates. Overweight/obese women with FADS1
SNPs showed the same trends and some nominal differences in DGLA and AA:DGLA, but
none of them with a p-value0.004. Other studies [1, 28, 29] have also found that FADS2




NORMAL-WEIGHT OVERWEIGHT/OBESITY P (MM) P (Mm+mm)
MM Mm+mm P MM Mm+mm P
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
ELOVL2 rs3798713 G/C 11 10.68 (2.24) 31 10.10 (2.20) 0.460 12 12.64 (1.58) 25 10.78 (2.55) 0.028 0.024 0.291
ELOVL2 rs953413 A/G 10 9.83 (2.22) 26 10.38 (1.99) 0.478 7 10.68 (2.80) 20 12.04 (2.09) 0.183 0.493 0.008
P-value derived from global ANOVA and significance level (p0.004) was adjusted for multiple testing by Bonferroni correction. Data are means of FAs
expressed as percentages of the total phospholipid profile (standard error). P-values <0.05 are highlighted in bold and significant associations that persisted
after Bonferroni correction are additionally denoted by stars or daggers (p0.004). *Indicates significant differences within each group of weight and †
Indicates significant differences between groups of weight. Major allele: M; minor allele: m; LA: Linoleic Acid; GLA: γ-Linolenic Acid; DGLA: Dihomo-γ-
Linolenic Acid; AA: Arachidonic Acid; AdA: Adrenic Acid; DPAn6: Docosapentaenoic acid n6; ALA: α-linolenic Acid; EPA: Eicosapentaenoic acid; DPAn3:
Docosapentaenoic acid n3; DHA: Docosahexaenoic acid.
https://doi.org/10.1371/journal.pone.0179135.t004
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Table 5. Substrates and products of enzymatic indexes according to maternal SNPs and LC-PUFA levels in plasma.
Gene SNP Major/minor
allele
NORMAL-WEIGHT OVERWEIGHT/OBESITY P (MM) P (Mm+mm)
MM Mm+mm P MM Mm+mm P
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
Fatty acids involved in FADS1 indexes
C20:3n-6 (DGLA)
FADS1 rs174537 G/T 15 3.51 (0.81) 23 4.27 (0.85) 0.010 12 3.31 (0.80) 21 4.18 (0.96) 0.012 0.529 0.754
FADS1 rs174545 C/G 22 3.50 (0.79) 27 4.14 (0.86) 0.009 13 3.39 (0.81) 22 4.15 (0.94) 0.021 0.691 0.976
FADS1 rs174546 C/T 22 3.50 (0.79) 27 4.14 (0.86) 0.009 13 3.39 (0.81) 25 4.11 (0.90) 0.021 0.691 0.893
FADS1 rs174548 C/G 24 3.59 (0.79) 25 4.10 (0.93) 0.041 13 3.38 (0.81) 25 4.11 (0.90) 0.019 0.431 0.969
FADS1 rs174553 A/G 22 3.50 (0.79) 27 4.14 (0.86) 0.009 13 3.39 (0.81) 25 4.11 (0.90) 0.021 0.691 0.893
FADS1 rs174547 T/C 15 3.61 (0.78) 23 4.17 (0.76) 0.036 12 3.31 (0.80) 20 4.17 (0.98) 0.016 0.335 0.980
C20:4n-6 (AA)
FADS1 rs174537 G/T 15 10.55 (1.33) 23 9.02 (1.54) 0.003* 12 10.53 (0.89) 21 10.04 (1.36) 0.273 0.973 0.026
FADS1 rs174545 C/G 22 10.50 (1.39) 27 8.96 (1.49) 0.001* 13 10.64 (0.93) 22 9.83 (1.31) 0.061 0.759 0.037
FADS1 rs174546 C/T 22 10.50 (1.39) 27 8.96 (1.49) 0.001* 13 10.64 (0.93) 25 9.90 (1.31) 0.080 0.759 0.019
FADS1 rs174548 C/G 24 10.28 (1.39) 25 9.05 (1.64) 0.007 13 10.40 (1.02) 25 10.03 (1.33) 0.389 0.790 0.025
FADS1 rs174553 A/G 22 10.50 (1.39) 27 8.96 (1.49) 0.001* 13 10.64 (0.93) 25 9.90 (1.31) 0.080 0.759 0.019
FADS1 rs174561 T/C 15 9.88 (1.32) 14 9.30 (1.12) 0.212 20 10.27 (1.48) 17 10.33 (1.54) 0.910 0.423 0.046
FADS1 rs174547 T/C 15 10.49 (1.33) 23 9.18 (1.47) 0.009 12 10.53 (0.89) 20 10.00 (1.38) 0.243 0.917 0.067
C18:3n-3 (ALA)
FADS1 rs174537 G/T 15 0.12 (0.04) 23 0.16 (0.04) 0.021 12 0.11 (0.03) 21 0.11 (0.04) 0.632 0.496 <0.001†
FADS1 rs174545 C/G 22 0.12 (0.04) 27 0.15 (0.04) 0.018 13 0.12 (0.03) 22 0.11 (0.04) 0.532 0.536 0.001†
FADS1 rs174546 C/T 22 0.12 (0.04) 27 0.15 (0.04) 0.018 13 0.12 (0.03) 25 0.11 (0.04) 0.580 0.536 0.001†
FADS1 rs174548 C/G 24 0.13 (0.04) 22 0.15 (0.04) 0.146 12 0.12 (0.03) 25 0.11 (0.04) 0.454 0.371 0.001
FADS1 rs174553 A/G 22 0.12 (0.04) 27 0.15 (0.04) 0.018 13 0.12 (0.03) 25 0.11 (0.04) 0.580 0.536 0.001†
FADS1 rs174561 T/C 15 0.13 (0.04) 14 0.13 (0.03) 0.695 20 0.12 (0.05) 17 0.11 (0.03) 0.497 0.397 0.024
FADS1 rs174547 T/C 15 0.12 (0.04) 23 0.15 (0.04) 0.027 12 0.11 (0.03) 20 0.11 (0.04) 0.734 0.444 <0.001†
C20:5n3 (EPA)
FADS1 rs174561 T/C 15 0.33 (0.14) 13 0.31 (0.11) 0.683 20 0.26 (0.11) 17 0.23 (0.10) 0.491 0.092 0.044
Fatty acids involved in FADS2 indexes
C20:3n-6 (DGLA)
FADS2 rs1535 A/G 20 3.41 (0.77) 25 4.23 (0.82) 0.001* 13 3.39 (0.81) 23 4.15 (0.92) 0.019 0.927 0.736
FADS2 rs174575 C/G 24 3.57 (0.71) 16 4.28 (0.97) 0.012 21 3.82 (1.30) 14 3.90 (0.90) 0.805 0.358 0.283
FADS2 rs174583 C/T 19 3.47 (0.75) 27 4.14 (0.86) 0.009 13 3.39 (0.81) 25 4.11 (0.90) 0.021 0.762 0.893
FADS2 rs99780 C/T 15 3.51 (0.78) 26 4.16 (0.89) 0.025 12 3.35 (0.84) 22 4.14 (0.94) 0.022 0.613 0.941
FADS2 rs174602 T/C 19 3.77 (0.82) 13 3.50 (0.85) 0.387 23 3.95 (0.76) 14 4.19 (0.54) 0.297 0.463 0.018
C20:4n-6 (AA)
FADS2 rs1535 A/G 20 10.31 (1.30) 25 9.07 (1.50) 0.005 13 10.64 (0.93) 23 9.92 (1.35) 0.102 0.439 0.044
FADS2 rs174583 C/T 19 10.33 (1.34) 27 8.96 (1.49) 0.003* 13 10.64 (0.93) 25 9.90 (1.31) 0.080 0.482 0.019
FADS2 rs99780 C/T 15 10.39 (1.48) 26 9.15 (1.51) 0.015 12 10.54 (0.91) 22 10.02 (1.40) 0.254 0.757 0.046
C18:3n-3 (ALA)
FADS2 rs1535 A/G 20 0.13 (0.04) 25 0.15 (0.04) 0.025 13 0.12 (0.03) 23 0.11 (0.04) 0.448 0.500 <0.001†
FADS2 rs174575 C/G 24 0.13 (0.04) 16 0.16 (0.04) 0.013 21 0.11 (0.03) 14 0.11 (0.03) 0.972 0.035 <0.001†
FADS2 rs174583 C/T 19 0.13 (0.04) 27 0.15 (0.04) 0.033 13 0.12 (0.03) 25 0.11 (0.04) 0.580 0.498 0.001†
FADS2 rs99780 C/T 15 0.13 (0.04) 26 0.15 (0.04) 0.060 12 0.12 (0.03) 22 0.11 (0.04) 0.584 0.576 0.001†
C20:5n-3 (EPA)
FADS2 rs174602 T/C 19 0.31 (0.14) 12 0.32 (0.10) 0.780 23 0.23 (0.09) 14 0.27 (0.13) 0.347 0.040 0.241
C22:5n-3 (DPAn3)
(Continued )
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for the normal-weight group, where minor allele carriers of FADS2 SNPs had significantly
lower levels of AA and higher DGLA. We also found nominal differences consistent with the
previous results (lower AA:LA index and higher ALA and DPAn3). Similarly to other studies
[30], the DGLA:LA index was nominally higher in minor allele carriers. This could be because
the DGLA:LA index precedes the AA:LA index and, therefore, a lower AA:LA index would
cause an accumulation of DGLA, thereby “increasing” the DGLA:LA index. Overweight/obese
women who were minor allele carriers of FADS2 SNPs only showed nominally higher levels of
DGLA than major homozygotes.
As shown previously, the FADS1 and FADS2 genetic variants were found to affect mainly




NORMAL-WEIGHT OVERWEIGHT/OBESITY P (MM) P (Mm+mm)
MM Mm+mm P MM Mm+mm P
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
FADS2 rs1535 A/G 20 0.41 (0.10) 25 0.42 (0.06) 0.730 13 0.42 (0.11) 23 0.37 (0.10) 0.190 0.887 0.034
FADS2 rs174575 C/G 24 0.40 (0.09) 16 0.44 (0.05) 0.056 21 0.39 (0.11) 14 0.37 (0.10) 0.632 0.872 0.033
FADS2 rs174583 C/T 19 0.40 (0.10) 27 0.42 (0.06) 0.388 13 0.42 (0.11) 25 0.37 (0.10) 0.158 0.674 0.018
FADS2 rs99780 C/T 15 0.38 (0.07) 26 0.44 (0.08) 0.017 12 0.42 (0.12) 22 0.39 (0.10) 0.429 0.297 0.043
C22:6n-3 (DHA)
FADS2 rs1535 A/G 20 4.48 (1.35) 25 4.23 (1.04) 0.496 13 4.56 (0.98) 23 4.18 (0.93) 0.255 0.841 0.869
FADS2 rs174575 C/G 24 4.19 (1.22) 16 4.50 (1.02) 0.400 21 4.25 (0.92) 14 4.44 (1.01) 0.573 0.856 0.859
FADS2 rs174583 C/T 19 4.31 (1.16) 27 4.29 (1.06) 0.955 13 4.56 (0.98) 25 4.11 (0.93) 0.169 0.528 0.511
FADS2 rs99780 C/T 15 4.14 (0.95) 26 4.33 (1.19) 0.599 12 4.64 (0.98) 22 4.26 (0.88) 0.260 0.188 0.835
FADS2 rs174602 T/C 19 4.32 (1.09) 13 4.52 (1.22) 0.635 23 4.10 (0.91) 14 4.19 (1.02) 0.794 0.480 0.450
Fatty acids involved in ELOVL2 indexes
C20:5n-3 (EPA)
ELOVL2 rs2236212 G/C 14 0.31 (0.12) 29 0.33 (0.15) 0.776 13 0.27 (0.23) 22 0.24 (0.11) 0.612 0.571 0.032
ELOVL2 rs3798713 G/C 11 0.32 (0.13) 31 0.34 (0.15) 0.765 12 0.28 (0.24) 25 0.24 (0.11) 0.490 0.626 0.011
C22:5n-3 (DPAn3)
ELOVL2 rs2236212 G/C 14 0.43 (0.10) 29 0.41 (0.07) 0.424 13 0.34 (0.06) 22 0.41 (0.12) 0.047 0.011 0.787
ELOVL2 rs3798713 G/C 11 0.43 (0.11) 31 0.41 (0.07) 0.465 12 0.35 (0.06) 25 0.41 (0.12) 0.099 0.033 0.992
C22:6n-3 (DHA)
ELOVL2 rs2236212 G/C 14 4.64 (1.32) 29 4.10 (0.98) 0.139 13 4.30 (0.99) 22 4.28 (0.97) 0.942 0.466 0.514
ELOVL2 rs3798713 G/C 11 4.60 (1.49) 31 4.10 (0.91) 0.200 12 4.41 (0.94) 25 4.24 (0.96) 0.617 0.728 0.565
ELOVL2 rs953413 A/G 10 3.82 (0.83) 26 4.31 (1.22) 0.250 7 3.85 (0.73) 20 4.61 (0.92) 0.059 0.929 0.357
Fatty acids involved in ELOVL5 indexes
C18:3n-3 (ALA)
ELOVL5 rs2397142 C/G 23 0.13 (0.04) 20 0.15 (0.04) 0.168 19 0.11 (0.03) 16 0.11 (0.04) 0.605 0.022 0.016
ELOVL5 rs9395855 T/G 6 0.16 (0.05) 25 0.14 (0.04) 0.405 8 0.10 (0.02) 20 0.11 (0.04) 0.519 0.010 0.047
C20:5n-3 (EPA)
ELOVL5 rs2397142 C/G 24 0.33 (0.14) 22 0.34 (0.14) 0.855 18 0.21 (0.09) 17 0.29 (0.22) 0.168 0.004† 0.411
P-value derived from global ANOVA and significance level (p0.004) was adjusted for multiple testing by Bonferroni correction. Data are means of FAs
expressed as percentages of the total phospholipid profile (standard error). P-values <0.05 are highlighted in bold and significant associations that persisted
after Bonferroni correction are additionally denoted by stars or daggers (p0.004). *Indicates significant differences within each group of weight and †
Indicates significant differences between groups of weight. Major allele: M; minor allele: m; LA: Linoleic Acid; GLA: γ-Linolenic Acid; DGLA: Dihomo-γ-
Linolenic Acid; AA: Arachidonic Acid; AdA: Adrenic Acid; DPAn6: Docosapentaenoic acid n6; ALA: α-linolenic Acid; EPA: Eicosapentaenoic acid; DPAn3:
Docosapentaenoic acid n3; DHA: Docosahexaenoic acid.
https://doi.org/10.1371/journal.pone.0179135.t005
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Several studies have observed that the DHA status, or that of the n-3 series, is less influenced
by genetic variants in the FADS genes [1, 5, 12, 13, 28, 31]. One possible explanation for this is
that the final conversion step from DPA to DHA requires translocation to the peroxisomes
(which is not performed in the endoplasmic reticulum where the other reactions occur) [1],
making DHA the least efficiently synthesized n-3 LC-PUFA. Therefore, the influence of SNPs
might not ultimately affect DHA levels [1, 32]. It has also been postulated that DHA supple-
mentation during pregnancy could reduce dependence on endogenous DHA synthesis [1].
However, previous studies have reported that increased dietary intake of EPA and DHA is
linked to higher FADS1 and lower FADS2 activities, suggesting that endogenous LC-PUFA
production remains active and is possibly enhanced, despite additional dietary intake of
LC-PUFAs [1, 33]. Moreover, in our study, we observed no differences in dietary intake of
EPA, DHA or AA between the two BMI groups; and although normal-weight pregnant
women were more likely to take DHA supplementation, it was very unusual and this supple-
mentation did not affect DHA level in plasma.
Our results suggest that BMI modifies genotype responses. According to FADS SNPs, n-6
FAs showed the same effects in the 2 groups studied, but significant effects were only found in
the group of normal-weight women. This suggests that overweight/obese women are less
affected. This could explain why women in the normal-weight group had significantly higher n-
3 substrate (ALA) levels and nominally lower n-6 product (AA) levels than overweight/obese
women, only when we compared minor allele carriers of SNPs in FADS1 and FADS2. Addition-
ally, among the minor allele carriers of FADS2, overweight/obese women showed significantly
higher DHA:EPA index than the normal-weight group (the DHA:DPAn3 index showed the
same trend). This suggests that minor alleles of FADS2 SNPS in overweight/obese women could
have a positive impact on n-3 LC-PUFA production. Furthermore, among major homozygotes,
overweight/obese women also showed nominally higher DHA:EPA index than those in the nor-
mal-weight group. Perhaps, regardless of genetic variants in the FADS gene, a high BMI could
be linked to increased activity of enzymes involved in n-3 FA synthesis. Nevertheless, there
were no differences in amounts of DHA between the weight groups, suggesting that even if
enzymatic activity in n-3 FA production is increased in overweight/obese individuals, it is not
enough to elicit greater n-3 LC-PUFA levels than in normal-weight subjects.
We analyzed 3 ELOVL2 SNPs (rs2236212, rs3798713 and rs953413) and found that their
genetic variants only affected n-3 FA levels in overweight/obese women. Overweight/obese
women who were minor allele carriers of rs2236212 [12] and rs3798713 had nominally lower
DHA:DPAn3 index compared with major homozygotes. This led to nominally higher amounts
of the substrate DPAn3. Lemaitre et al. found decreased DHA levels in the presence of at least
one minor allele of rs2236212 [15], which is consistent with the tendency observed in our
results. The normal-weight group generally showed the same trends. Moreover, among minor
allele carriers of ELOVL2 SNPs, overweight/obese women showed significantly higher DHA:
EPA index than normal-weight women (DPA:EPA and DHA:DPA indexes showed the same
tendency). This is in accordance with FADS2 results. Therefore, minor alleles of FADS2 and
ELOVL2 SNPs in overweight/obese women, could increase n-3 LC-PUFA production indexes,
but without surpassing levels in normal-weight women.
Estrogen facilitates LC-PUFA synthesis [34, 35], probably by regulating delta-6 desaturase.
During pregnancy, estrogen levels are higher, leading to increased amounts of DHA and AA
until delivery, when the release of prolactin inhibits estrogen activity [35]. Since estrogen is
produced in adipocytes, obesity is linked to high estrogen levels which increase proportionally
to total body adiposity [36]. This could be an alternative explanation of the increase in n-3
LC-PUFA production observed in overweight/obese individuals. In this case, more studies
introducing measurements of estrogen in both populations are needed.
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We also studied n3:n6 ratios (EPA:AA and DHA:AA), which are associated with obesity
risk. Among minor allele carriers of the FADS and ELOVL genes, normal-weight women
showed nominally higher plasma ratios of EPA:AA and DHA:AA than women who were over-
weight/obese. The same trend was observed when comparing major homozygotes, but with a
weaker (or no) association. This suggests that a high BMI leads to increased levels of AA and/
or lower levels of DHA and EPA, more importantly in women who carry at least one copy of
the minor allele of FADS and ELOVL SNPs.
To the best of our knowledge, this is the first report to directly associate FADS SNPs with
obesity risk and to analyze how weight affects the impact of variations in genes involved in FA
metabolism. Our results further justify the need for personalized nutrition by showing that
metabolism is affected by nutritional status and genes. Our present study had some limitations:
it might be limited by the relatively small sample size; however, we could identify and group
participants into different weight and genotype categories. Information on dietary intake was
obtained from validated food records and questionnaires and although each participant was
guided by a nutritionist, this information could have been affected by recall bias. Likewise, sup-
plementation data (brand, content, doses and frequency) during pregnancy were also obtained
from questionnaires answered by the participants; therefore, this information might not be
completely accurate.
Conclusions
In conclusion, minor allele carriers of FADS1 and FADS2 SNPs have an increased risk of obe-
sity (p0.05). The effects of genotype on FA concentrations differed by maternal pre-preg-
nancy weight status. Enzymatic activity and FA levels were reduced in normal-weight women
who were minor allele carriers of FADS SNPs; these reductions were not significant in over-
weight/obese participants. This suggests that women with a BMI25 are less affected by FADS
genetic variants in this regard. In the presence of FADS2 and ELOVL2 SNPs, overweight/
obese women showed higher n-3 LC-PUFA production indexes than those women in the nor-
mal-weight group, but this was not enough to obtain a higher n-3 LC-PUFA concentration
(p0.004). Since genotypes may not have the same effects on all people, it is of interest to con-
tinue exploring gene-BMI interactions to pursue personalized health-related recommenda-
tions. Alterations in maternal FAs modify the risk of pro-inflammatory diseases and affect FA
delivery to the fetus/neonate, which has an impact on child growth and development. There-
fore, this study also supports the importance of a healthy pre-pregnancy weight, and identifies
groups of women who could benefit from a high intake of n-3 FAs in order to achieve an
improved FA status that fulfills fetal/neonatal requirements.
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